Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers

This study was designed to assess the pharmacokinetics of almotriptan, a 5- HT1B/1D agonist, when administered in the presence and absence of propranol ol. Healthy male (n = 10) and female (n =2) volunteers received (i) 80 mg p ropranolol twice daily for 7 days and 12.5 mg almotriptan on day 7, and (ii ) 12.5 mg almotriptan on day 7, according to a two-way crossover design. Pl asma and urinary almotriptan concentrations were measured by high performan ce liquid chromatography (HPLC) methods. Treatment effects on pharmacokinet ic parameters were assessed by analysis of variance (ANOVA). Statistically significant differences between treatments in area under the curve (AUC), c learance, and half-life were observed (P < 0.03), but these differences wer e <7%. Ninety percent confidence interval analysis of log-transformed pharm acokinetic parameters showed that the treatments were equivalent. Adverse e vents were mild to moderate in intensity, and no treatment effects on vital signs were observed. The results show that propranolol has no effect on th e pharmacokinetics of almotriptan. Concomitant administration of the two dr ugs is well tolerated.